Rigel Pharmaceuticals (RIGL) Raw Materials (2021 - 2026)

Rigel Pharmaceuticals' Raw Materials history runs 6 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Raw Materials rose 218.2% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 218.2% increase from a year earlier, with the FY2025 full-year figure at $4.5 million, up 319.13% from the prior year.
• Raw Materials slipped to $3.4 million in Q1 2026 per RIGL's latest filing, from $4.5 million in the prior quarter.
• Across five years, Raw Materials topped out at $9.6 million in Q2 2025 and bottomed at $1.1 million in Q4 2024.
• The 5-year median for Raw Materials is $4.6 million (2022), against an average of $4.4 million.
• Across the five-year window, Raw Materials tumbled 76.63% in 2024 and jumped 348.76% in 2025, its largest moves.
• Year by year, Raw Materials stood at $4.6 million in 2022, then climbed by 1.19% to $4.6 million in 2023, then tumbled by 76.63% to $1.1 million in 2024, then surged by 319.13% to $4.5 million in 2025, then dropped by 24.08% to $3.4 million in 2026.
• Per Business Quant, the three latest RIGL Raw Materials figures stand at $3.4 million (Q1 2026), $4.5 million (Q4 2025), and $7.0 million (Q3 2025).